Sequel Pharmaceuticals, Inc.

Privately-held biopharmaceutical company Sorbent Therapeutics has appointed Dr Howard Dittrich its first chief medical officer and Randall Woods chair of the board of directors. Dr Dittrich has over 2

Sophiris Bio will use a transrectal route of administration, rather than the transperineal route, for its lead drug PRX302 for the treatment of Benign Prostatic Hyperplasia (BPH or enlarged prostate).

New company creation slipped significantly in 2009 as venture capitalists conserved capital and supported existing portfolio companies. In biopharmaceuticals, corporate venture got in at the ground fl

Despite continuing pharmacological and physiological advances, ongoing public health campaigns, and well established guidelines defining challenging treatment targets, cardiovascular disease (CVD) kil